3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
3
Oropharyngeal Neoplasms
3
Neoplasm Metastasis
3
Uterine Cervical Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Ovarian Neoplasms
2
Multiple Myeloma
2
Mouth Neoplasms
2
Melanoma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hodgkin Disease
2
Cholangiocarcinoma
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Uveal Melanoma
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Stage III Lung Non-Small Cell Cancer AJCC v7
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Rectal Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms
1
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
amino-acid, glucose, and electrolyte solution
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Fluorodeoxyglucose F18
×
90 days
×
Clear all
No trials found.